Real-World Evidence Demonstrates the Highest Response and Remission Rates Observed to Date for Deep BURLINGTON, Mass. and JERUSALEM, March 28, 2023...
On track to complete enrollment in Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer’s disease in mid-2023 with topline...
- Completed enrollment of CT1812 Phase 2 SEQUEL study for mild-to-moderate Alzheimer's disease - Received FDA clearance for Phase 2...
-- Agreement extends existing partnership ---- Collaboration makes HealthTech Connex the exclusive provider of PoNS Therapy in the Vancouver area...
Award recognizes NeuroStar for its significant contributions toward patient wellbeingMALVERN, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:...
Conference Call and Live Audio Webcast Scheduled for Wednesday, March 23, 2023, 8:00 a.m. ETPURCHASE, N.Y., March 16, 2023 (GLOBE...
TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 13, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology...
MaxCyte’s Scientific Advisory Board will provide guidance to shape the technical direction of the company’s innovation initiatives focused on the...
March 20, 2023 at 11:00 AM ETPORTLAND, Maine, March 08, 2023 (GLOBE NEWSWIRE) -- MedRhythms today announced it will host...
OV350 is the first reported compound that directly binds to and activates the KCC2 co-transporter, a target implicated in neuronal...
NEW YORK, March 03, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data...
VANCOUVER, British Columbia, March 02, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or...
Hashad is a former executive at Avanir, Amgen, Boehringer Ingelheim, Eli Lilly, and early-stage biotechnology companies Global leader brings over...
If approved, niraparib in combination with abiraterone acetate (AA), will be the first dual action tablet (DAT) available in the European...
NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting data from the ULTIMATE I...
Company Launches a New Educational Campaign For ProvidersMALVERN, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a...
Event theme, “MS: Going Viral” touches on the role of viruses in MS, particularly Epstein-Barr, a topic related to Company’s...
BURLINGTON, Mass. and JERUSALEM, Feb. 23, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
– Initiated multiple trials with ARV-471, including a 2L+ Phase 3 trial for patients with metastatic breast cancer – – Presented Phase...
Poster Session Highlights the Strong Dose-Response Relationship and the Importance of Treating Beyond 30 Treatments With NeuroStar Advanced TherapyMALVERN, Pa.,...